Patients with low levels of high-density lipoprotein cholesterol: To treat or not to treat?

Singapore Medical Journal

Volumn 46, Issue 10, 2005, Pages 519-528

  Tavintharan, S ^a   Lim, S C ^a,b   Sum, C F ^a,c  

^a ALEXANDRA HOSPITAL   (Singapore)

^b Clinical Research

^c Diabetes Centre

Author keywords

Apolipoprotein A I; Atherosclerosis; High density lipoprotein; Hypoalphalipoproteinaemia

Indexed keywords

ANTILIPEMIC AGENT; ANTIOXIDANT; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN C; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; COLESTIPOL; COLESTYRAMINE; ESTROGEN; ETC 216; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GESTAGEN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH DENSITY LIPOPROTEIN MIMETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; OVASTATIN; PRAVASTATIN; PROTEIN DERIVATIVE; SIMVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL PROTOCOL; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; DYSLIPIDEMIA; FIBRINOLYSIS; FOLLOW UP; HEART INFARCTION; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; INTRAVASCULAR ULTRASOUND; LIFESTYLE; NONHUMAN; OUTCOMES RESEARCH; PRIMARY PREVENTION; REVIEW; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; THROMBOCYTE AGGREGATION INHIBITION; TRIACYLGLYCEROL BLOOD LEVEL;

ANTILIPEMIC AGENTS; APOPROTEINS; ARTERIOSCLEROSIS; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CLOFIBRIC ACID; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; ETHANOL; EXERCISE; GEMFIBROZIL; GLYCOPROTEINS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIFE STYLE; NIACIN;

EID: 26044436054     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79:8-15.
2. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1975; 1:16-9.
3. Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997; 17:107-13.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97.
5. American Diabetes Association. Management of dyslipidemia in adult men with diabetes. Diabetes Care 2000; 23 (supp 1):S57-60.
6. Rubins HB, Robins SJ, Collins D, et al. Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. Am J Cardiol 1995; 75:1196-201.
7. Martin MJ, Hulley SB, Browner WS, et al. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet 1986; 2:933-6.
8. Manninen V, Huttunen JK, Heinonen OP, et al. Relation between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart Study. Am J Cardiol 1989; 63:42-7H.
9. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615-22.
10. Pasternak RC, Brown LE, Stone PH, et al. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group. Ann Intern Med 1996; 125:529-40.
11. Stewart BF, Brown BG, Zhao XQ, et al. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol. J Am Coll Cardiol 1994; 23:899-906.
12. Frick MH, Syvanne M, Nieminen MS, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997; 96:2137-43.
13. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345:1583-92.
14. Ruotolo G, Ericsson CG, Tettamanti C, et al. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol 1998; 32:1648-56.
15. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341:410-8.
16. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001; 285:1585-91.
17. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102:21-7.
18. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
19. Barkia A, Puchois P, Ghalim N, et al. Differential role of apolipoprotein AI-containing particles in cholesterol efflux from adipose cells. Atherosclerosis 1991; 87:135-46.
20. Rust S, Rosier M, Funke H, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 1999; 22:352-5.
21. Saku K, Ahmad M, Glas-Greenwalt P, et al. Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. Thromb Res 1985; 39:1-8.
22. Henriksen T, Mahoney EM, Steinberg D. Interaction of plasma lipoproteins with endothelial cells. Ann N Y Acad Sci 1982; 401:102-16.
23. Yui Y, Aoyama T, Morishita H, et al. Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (ApoA-I). A novel function of Apo A-I. J Clin Invest 1988; 82:803-7.
24. Berns MA, de Vries JH, Katan MB. Increase in body fatness as a major determinant of changes in serum total cholesterol and high density lipoprotein cholesterol in young men over a 10-year period. Am J Epidemiol 1989; 130:1109-22.
25. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990; 336:129-33.
26. Brehm BJ, Seeley RJ, Daniels SR, et al. A randomized trial comparing a very low carbohydrate diet and a calorie-restricted low fat diet on body weight and cardiovascular risk factors in healthy women. J Clin Endocrinol Metab 2003; 88:1617-23.
27. Sagiv M, Goldbourt U. Influence of physical work on high density lipoprotein cholesterol: implications for the risk of coronary heart disease. Int J Sports Med 1994; 15:261-6.
28. Kraus WE, Houmard JA, Duscha BD, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 2002; 347:1483-92.
29. Criqui MH, Wallace RB, Heiss G, et al. Cigarette smoking and plasma high-density lipoprotein cholesterol. The Lipid Research Clinics Program Prevalence Study. Circulation 1980; 62(4 Pt 2):IV 70-6.
30. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-34.
31. Castelli WP, Abbott RD, McNamara PM. Summary estimates of cholesterol used to predict coronary heart disease. Circulation 1983; 67:730-4.
32. Stampfer MJ, Sacks FM, Salvini S, et al. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991; 325:373-81.
33. Jin FY, Kamanna VS, Chuang MY, et al. Gemfibrozil stimulates apolipoprotein A-I synthesis and secretion by stabilization of mRNA transcripts in human hepatoblastoma cell line (Hep G2). Arterioscler Thromb Vasc Biol 1996; 16:1052-62.
34. Steiner G. Treating lipid abnormalities in patients with type 2 diabetes mellitus. Am J Cardiol 2001; 88:37N-40N.
35. Sakai T, Kamanna VS, Kashyap ML. Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol 2001; 21:1783-9.
36. Jin FY, Kamanna VS, Kashyap ML. Niacin accelerates intracelluar ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler Thromb Vasc Biol 1999, 19:1051-9.
37. Ganji SH, Tavintharan S, Zhu D, et al. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res. 2004; 45:1835-45.
38. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002; 162:1568-76.
39. Guyton JR, Blazing BA, Hagar J, et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Arch Intern Med 2000; 160:1177-84.
40. Zema MJ. Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study. J Am Coll Cardiol 2000; 35:640-6.
41. Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002; 89:672-8.
42. Napoli C, Leccese M, Palumbo G, et al. Effects of vitamin E and HMG-CoA reductase inhibition on cholesteryl ester transfer protein and lecithin-cholesterol acyltransferase in hypercholesterolemia. Coron Artery Dis 1998; 9:257-64.
43. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350:1495-504.
44. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227-39.
45. Erratum in: Circulation 2004; 110:763.
46. Brown ML, Inazu A, Hesler CB, et al. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature 1989; 342:448-51.
47. Gaynor BJ, Sand T, Clark RW, et al. Inhibition of cholesteryl ester transfer protein activity in hamsters alters HDL lipid composition. Atherosclerosis 1994; 110:101-9.
48. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004; 350:1505-15.
49. Sirtori CR, Calabresi L, Franceschini G, et al. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation 2001; 103:1949-54.
50. Rader DJ. High-density lipoproteins and atherosclerosis. Am J Cardiol 2002; 90:62i-70i.
51. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290:2292-300.
52. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/protestin Replacement Study (HERS) Research Group. JAMA 1998; 280:605-13.
53. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-33.
54. Beaglehole R, Jackson R. Alcohol, cardiovascular diseases and all causes of death: a review of the epidemiological evidence. Drug Alcohol Rev 1992; 11:275-90.
55. Marmot M, Brunner E. Alcohol and cardiovascular disease: the status of the U shaped curve. BMJ 1991; 303:565-8.
56. Malmendier CL, Delcroix C. Effect of alcohol intake on high and low density lipoprotein metabolism in healthy volunteers. Clin Chim Acta 1985; 152:281-8.
57. Langer RD, Criqui MH, Reed DM. Lipoproteins and blood pressure as biological pathways for effect of moderate alcohol consumption on coronary heart disease. Circulation 1992; 85:910-5.